Janssen Announces U.S. FDA Approval of INVEGA HAFYERA™
https://www.jnj.com/media-center/press-releases/janssen-announces-u-s-fda-approval-of-invega-hafyera-6-month-paliperidone-palmitate-first-and-only-twice-yearly-treatment-for-adults-with-schizophrenia
WEBSeptember 01, 2021. TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of ...
DA: 39 PA: 27 MOZ Rank: 76